Novo’s Wegovy becomes first GLP-1 drug approved for MASH

The FDA has granted accelerated approval to Novo Nordisk's Wegovy for metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver scarring, marking the first GLP-1 agonist cleared for the condition affecting an estimated 22 million Americans. This approval introduces a significant competitor to Madrigal Pharmaceuticals' Rezdiffra, the only other approved MASH therapy, leading to a slump in Madrigal shares despite Rezdiffra's strong initial sales performance. While analysts anticipate some MASH patients, particularly those with underlying metabolic conditions, may opt for Wegovy, they also project continued robust uptake for Rezdiffra among other patient segments, creating a nuanced competitive landscape that investors are closely monitoring for shifts in treatment guidelines and insurer preferences.

Analysis

The U.S. Food and Drug Administration has granted accelerated approval for Novo Nordisk's Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH), making it the first GLP-1 agonist cleared for this condition in a market estimated to affect 22 million Americans. This approval positions Wegovy, already a multibillion-dollar obesity drug, as a direct competitor to Madrigal Pharmaceuticals' Rezdiffra, which was previously the only therapy specifically approved for MASH. The market reacted swiftly, with Madrigal's shares slumping on the news, reflecting investor concern over the new competitive threat despite Rezdiffra's stronger-than-expected launch that generated $180 million in sales in 2024 and $350 million in the first half of 2025. Analyst commentary suggests a nuanced market dynamic, where Wegovy may be preferred for MASH patients with underlying metabolic conditions, but Rezdiffra is expected to maintain a robust market share among sizable patient sub-segments, including those who are already on competing GLP-1s like Eli Lilly's Zepbound or are considered 'lean'. Furthermore, the FDA's decision is viewed as a positive signal for the broader MASH drug development landscape, potentially benefiting other companies with therapies in advanced testing such as Akero Therapeutics, 89bio, and Sagimet Biosciences.

Key Decisions for Investors

• The expanded label for Novo Nordisk's Wegovy significantly increases its total addressable market and diversifies its revenue stream, reinforcing the long-term growth thesis for the stock.
• Investors in Madrigal Pharmaceuticals should re-evaluate peak sales forecasts for Rezdiffra, as the entry of a major competitor like Wegovy introduces significant market share risk and potential pressure from insurers to adopt step-therapy.
• The FDA's willingness to grant accelerated approval in this space may de-risk the regulatory pathway for other MASH-focused biotechs, making late-stage pipeline assets from companies like Akero, 89bio, and Sagimet worthy of increased monitoring.
• Key factors to monitor will be the evolving treatment guidelines and insurer reimbursement policies, which will ultimately determine the real-world market segmentation between multi-indication GLP-1 therapies and dedicated MASH drugs.